The HSP47 siRNA BMS-986263 [88] and the JNK inhibitor CC-90001 (ClinicalTrials.gov identifier: NCT04048876; recruitment status indicated that it is terminated (business objectives have changed)) have been evaluated for their therapeutic effects on liver fibrosis in NAFLD. This evidence concerns the gene SERPINH1 and metabolic dysfunction-associated steatotic liver disease.